Latest Articles

Publication Date
All News Scientific
Recurrent IVF Failure isn’t the End of Journey; Personalised Treatment is Improving Success Rates: Fertility Experts - IndiaMedToday

Recurrent IVF Failure isn’t the End of Journey; Personalised Treatment is Improving Success Rates: Fertility Experts IndiaMedToday

Published: July 25, 2026, 4:03 a.m.
Read Full Article
Recurrent IVF Failure isn’t the End of Journey ; Personalised Treatment is Improving Success Rates: Fertility Experts - 5 Dariya News

Recurrent IVF Failure isn’t the End of Journey ; Personalised Treatment is Improving Success Rates: Fertility Experts 5 Dariya News

Published: July 23, 2026, 7:34 a.m.
Read Full Article
Recurrent IVF Failure isn’t the End of Journey; Personalised Treatment is Improving Success Rates: Fertility Experts - Modern Ghana

Recurrent IVF Failure isn’t the End of Journey; Personalised Treatment is Improving Success Rates: Fertility Experts Modern Ghana

Published: July 22, 2026, 1:11 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace

Published: July 15, 2026, 3:11 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire

Published: July 15, 2026, 10:45 a.m.
Read Full Article
Palbociclib Plus Anastrozole Is Safe and Effective in ER+ Recurrent Endometrial Cancer - OncLive

Palbociclib Plus Anastrozole Is Safe and Effective in ER+ Recurrent Endometrial Cancer OncLive

Published: June 19, 2026, 1:08 p.m.
Read Full Article
Mocertatug Rezetecan Drives Rapid, Deep Responses in Platinum-Resistant Ovarian and Recurrent/Advanced Endometrial Cancer - OncLive

Mocertatug Rezetecan Drives Rapid, Deep Responses in Platinum-Resistant Ovarian and Recurrent/Advanced Endometrial Cancer OncLive

Published: June 17, 2026, 9:11 p.m.
Read Full Article
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer - The ASCO Post

Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer The ASCO Post

Published: June 3, 2026, 2:49 p.m.
Read Full Article
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - MSN

Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer MSN

Published: June 2, 2026, 12:41 a.m.
Read Full Article
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - Medical Xpress

Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer Medical Xpress

Published: June 1, 2026, 8 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!